This Article  • Full text  • PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (120)  • Contact me when this article is cited  Related Content  • Related letter  • Similar articles in JAMA  Topic Collections  • Nutritional and Metabolic Disorders  • Lipids and Lipid Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Results From the DCCT

Jonathan Q. Purnell, MD; John E. Hokanson, MPH, PhD; Santica M. Marcovina, PhD; Michael W. Steffes, MD, PhD; Patricia A. Cleary, MS; John D. Brunzell, MD

JAMA. 1998;280:140-146.

Context.— Intensive treatment of type 1 diabetes results in greater weight gain than conventional treatment.

Objective.— To determine the effect of this weight gain on lipid levels and blood pressure.

Design.— Randomized controlled trial; ancillary study of the Diabetes Control and Complications Trial (DCCT).

Setting.— Twenty-one clinical centers.

Participants.— The 1168 subjects enrolled in DCCT with type 1 diabetes who were aged 18 years or older at baseline.

Intervention.— Randomized to receive either intensive (n=586) or conventional (n=582) diabetes treatment with a mean follow-up of 6.1 years.

Main Outcome Measures.— Plasma lipid levels and blood pressure in each treatment group categorized by quartile of weight gain.

Results.  —With intensive treatment, subjects in the fourth quartile of weight gain had the highest body mass index (BMI) (a measure of weight adjusted for height), blood pressure, and levels of triglyceride, total cholesterol, low-density lipoprotein cholesterol (LDL-C), and apolipoprotein B compared with the other weight gain quartiles with the greatest difference seen when compared with the first quartile (mean values for the highest and lowest quartiles: BMI, 31 vs 24 kg/m²; blood pressure, 120/77 mm Hg vs 113/73 mm Hg; triglyceride, 0.99 mmol/L vs 0.79 mmol/L [88 mg/dL vs 70 mg/dL]; LDL-C, 3.15 mmol/L vs 2.74 mmol/L [122 mg/dL vs 106 mg/dL]; and apolipoprotein B, 0.89 g/L vs 0.78 g/L; all P<.001). In addition, the fourth quartile group had a higher waist-to-hip ratio; more cholesterol in the very low density lipoprotein, intermediate dense lipoprotein, and dense LDL fractions; and lower high-density lipoprotein cholesterol and apolipoprotein A-I levels compared with the first quartile. Baseline characteristics were not different between the first and fourth quartiles of weight gain with intensive therapy except for a higher hemoglobin A_1c in the fourth quartile. Weight gain with conventional therapy resulted in smaller increases in BMI, lipids, and systolic blood pressure.

Conclusions.— The changes in lipid levels and blood pressure that occur with excessive weight gain with intensive therapy are similar to those seen in the insulin resistance syndrome and may increase the risk of coronary artery disease in this subset of subjects with time.

From the Division of Metabolism, Endocrinology, and Nutrition, Department of Medicine (Drs Purnell, Hokanson, Marcovina, and Brunzell), and the Department of Epidemiology, School of Public Health and Community Medicine (Dr Hokanson), University of Washington, Seattle; Diabetes Control and Complications Trial Coordinating Center, Biostatistics Center, The George Washington University, Rockville, Md (Ms Cleary); and Department of Laboratory Medicine, University of Minnesota, Minneapolis (Dr Steffes). Dr Steffes and Ms Cleary are members of the Diabetes Control and Complications Trial Research Group.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

RELATED LETTER

Drug Therapy for Patients With Type 2 Diabetes
John M. Poothullil, Nasser Mikhail, and Silvio E. Inzucchi
JAMA. 2002;287(13):1645-1646.
EXTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Prevalence of Abnormal Lipid Profiles and the Relationship With the Development of Microalbuminuria in Adolescents With Type 1 Diabetes
Loredana Marcovecchio et al.
Diabetes Care 2009;32:658-663.
ABSTRACT | FULL TEXT  

Insulin Therapy, Hyperglycemia, and Hypertension in Type 1 Diabetes Mellitus
de Boer et al.
Arch Intern Med 2008;168:1867-1873.
ABSTRACT | FULL TEXT  

Insulin Analogs: Impact on Treatment Success, Satisfaction, Quality of Life, and Adherence
Hartman
Clin Med Res 2008;6:54-67.
ABSTRACT | FULL TEXT  

Resolving the Conundrum of Islet Transplantation by Linking Metabolic Dysregulation, Inflammation, and Immune Regulation
Huang et al.
Endocr. Rev. 2008;29:603-630.
ABSTRACT | FULL TEXT  

Body Composition Indices in Women With Well-Controlled Type 1 Diabetes
Dube et al.
Diabetes Care 2008;31:e48-e48.
FULL TEXT  

Cardiovascular Disease in Diabetes
Bloomgarden
Diabetes Care 2008;31:1260-1266.
FULL TEXT  

Diabetes and Obesity: Part 2
Bloomgarden
Diabetes Care 2008;31:176-182.
FULL TEXT  

Body Weight Changes Associated With Insulin Therapy: A retrospective pooled analysis of inhaled human insulin (Exubera) versus subcutaneous insulin in five controlled Phase III trials
Hollander et al.
Diabetes Care 2007;30:2508-2510.
FULL TEXT  

Anti-Diabetes and Anti-Obesity Medications: Effects on Weight in People With Diabetes
Hollander
Diabetes Spectr. 2007;20:159-165.
ABSTRACT | FULL TEXT  

Insulin Resistance, the Metabolic Syndrome, and Complication Risk in Type 1 Diabetes: "Double diabetes" in the Diabetes Control and Complications Trial
Kilpatrick et al.
Diabetes Care 2007;30:707-712.
ABSTRACT | FULL TEXT  

Through the Looking Glass: Current and Future Perspectives on the Role of Hormonal Interplay in Glucose Homeostasis
Kruger et al.
The Diabetes Educator 2007;33:32S-46S.
FULL TEXT  

Central Obesity, Incident Microalbuminuria, and Change in Creatinine Clearance in the Epidemiology of Diabetes Interventions and Complications Study
de Boer et al.
J. Am. Soc. Nephrol. 2007;18:235-243.
ABSTRACT | FULL TEXT  

Type 1 diabetes and coronary artery disease.
Orchard et al.
Diabetes Care 2006;29:2528-2538.
FULL TEXT  

A Double-Blind, Placebo-Controlled Trial Assessing Pramlintide Treatment in the Setting of Intensive Insulin Therapy in Type 1 Diabetes
Edelman et al.
Diabetes Care 2006;29:2189-2195.
ABSTRACT | FULL TEXT  

Nocturnal Hypoglycemia-- An Unrelenting Problem
Chase
J. Clin. Endocrinol. Metab. 2006;91:2038-2039.
FULL TEXT  

A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes.
Hermansen et al.
Diabetes Care 2006;29:1269-1274.
ABSTRACT | FULL TEXT  

Amylin Replacement Therapy in Patients With Type 1 Diabetes
Edelman and Caballero
The Diabetes Educator 2006;32:119S-127S.
ABSTRACT | FULL TEXT  

Challenges and strategies for moving patients to injectable medications.
Siminerio
The Diabetes Educator 2006;32:82S-90S.
FULL TEXT  

Emerging Therapies Mimicking the Effects of Amylin and Glucagon-Like Peptide 1
Riddle and Drucker
Diabetes Care 2006;29:435-449.
FULL TEXT  

Impact of Overweight on Chronic Microvascular Complications in Type 1 Diabetic Patients
De Block et al.
Diabetes Care 2005;28:1649-1655.
ABSTRACT | FULL TEXT  

Report of the National Heart, Lung, and Blood Institute-National Institute of Diabetes and Digestive and Kidney Diseases Working Group on Cardiovascular Complications of Type 1 Diabetes Mellitus
Libby et al.
Circulation 2005;111:3489-3493.
FULL TEXT  

Inflammation and Cardiovascular Disease in Patients With Diabetes: Lessons From the Diabetes Control and Complications Trial
Festa and Haffner
Circulation 2005;111:2414-2415.
FULL TEXT  

Effect of Intensive Glycemic Control on Levels of Markers of Inflammation in Type 1 Diabetes Mellitus in the Diabetes Control and Complications Trial
Schaumberg et al.
Circulation 2005;111:2446-2453.
ABSTRACT | FULL TEXT  

Weight gain and insulin therapy
Khan
British Journal of Diabetes & Vascular Disease 2004;4:264-267.
ABSTRACT  

Glucose Metabolism and Regulation: Beyond Insulin and Glucagon
Aronoff et al.
Diabetes Spectr. 2004;17:183-190.
ABSTRACT | FULL TEXT  

Insulin Detemir Offers Improved Glycemic Control Compared With NPH Insulin in People With Type 1 Diabetes: A randomized clinical trial
Home et al.
Diabetes Care 2004;27:1081-1087.
ABSTRACT | FULL TEXT  

Relationship of Family History of Type 2 Diabetes, Hypoglycemia, and Autoantibodies to Weight Gain and Lipids With Intensive and Conventional Therapy in the Diabetes Control and Complications Trial
Purnell et al.
Diabetes 2003;52:2623-2629.
ABSTRACT | FULL TEXT  

Effect on Glycemic Control of Exenatide (Synthetic Exendin-4) Additive to Existing Metformin and/or Sulfonylurea Treatment in Patients With Type 2 Diabetes
Fineman et al.
Diabetes Care 2003;26:2370-2377.
ABSTRACT | FULL TEXT  

Insulin Resistance-Related Factors, but not Glycemia, Predict Coronary Artery Disease in Type 1 Diabetes: 10-year follow-up data from the Pittsburgh Epidemiology of Diabetes Complications study
Orchard et al.
Diabetes Care 2003;26:1374-1379.
ABSTRACT | FULL TEXT  

Secular trends in growth in diabetes: are we winning?
Donaghue et al.
Arch. Dis. Child. 2003;88:151-154.
ABSTRACT | FULL TEXT  

Treatment of Type 2 Diabetes: The American Association of Clinical Endocrinologists Meeting, May 2002
Bloomgarden
Diabetes Care 2002;25:1644-1649.
FULL TEXT  

Amylin Replacement With Pramlintide in Type 1 and Type 2 Diabetes: A Physiological Approach to Overcome Barriers With Insulin Therapy
Buse et al.
Clin. Diabetes 2002;20:137-144.
ABSTRACT | FULL TEXT  

Drug Therapy for Patients With Type 2 Diabetes
Poothullil et al.
JAMA 2002;287:1645-1646.
FULL TEXT  

A Randomized Study and Open-Label Extension Evaluating the Long-Term Efficacy of Pramlintide as an Adjunct to Insulin Therapy in Type 1 Diabetes
Whitehouse et al.
Diabetes Care 2002;25:724-730.
ABSTRACT | FULL TEXT  

Evidence-Based Nutrition Principles and Recommendations for the Treatment and Prevention of Diabetes and Related Complications
Franz et al.
Diabetes Care 2002;25:148-198.
FULL TEXT  

Candesartan Inhibits Carotid Intimal Thickening and Ameliorates Insulin Resistance in Balloon-Injured Diabetic Rats
Igarashi et al.
Hypertension 2001;38:1255-1259.
ABSTRACT | FULL TEXT  

Gene and Cell-Replacement Therapy in the Treatment of Type 1 Diabetes: How High Must the Standards Be Set?
Halban et al.
Diabetes 2001;50:2181-2191.
ABSTRACT | FULL TEXT  

Rise in Albuminuria and Blood Pressure in Patients Who Progressed to Diabetic Nephropathy in the Diabetes Control and Complications Trial
THOMAS et al.
J. Am. Soc. Nephrol. 2001;12:333-340.
ABSTRACT | FULL TEXT  

Prevalence and Phenotypic Distribution of Dyslipidemia in Type 1 Diabetes Mellitus: Effect of Glycemic Control
Perez et al.
Arch Intern Med 2000;160:2756-2762.
ABSTRACT | FULL TEXT  

Excessive Weight Gain and Effects on Lipids With Intensive Therapy of Type 1 Diabetes
Wei et al.
JAMA 1998;280:1991-19921.
FULL TEXT  

Intensive Insulin Therapy for Type 1 Diabetes: Gains and Losses
Journal Watch Dermatology 1998;1998:15-15.
FULL TEXT  

Intensive Insulin Therapy for Type 1 Diabetes: Gains and Losses.
JWatch General 1998;1998:1-1.
FULL TEXT